CoChat

RETRACTED: Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon

Open access
Samaha, Ali, Mouawia, Hussein, Fawaz, Mirna, Hassan, Hamad, Salami, Ali, Bazzal, Ali, Saab, Hamid, Al-Wakeel, Mohamed, Alsaabi, Ahmad, Chouman, Mohamad, Moussawi, Mahmoud, Ayoub, Hassan, Raad, Ali, Hajjeh, Ola, Eid, Ali, Raad, Houssam · 2021 · Viruses
Cited by 37

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Objective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that have tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose (according to body weight) of ivermectin, in addition to the same supplements the control group received. Results: There was no significant difference (p = 0.06) between Ct-values of the two groups before the regimen was started (day zero), indicating that subjects in both groups had similar viral loads. At 72 h after the regimen started, the increase in Ct-values was dramatically higher in the ivermectin than in the control group. In the ivermectin group, Ct increased from 15.13 ± 2.07 (day zero) to 30.14 ± 6.22 (day three; mean ± SD), compared to the control group, where the Ct values increased only from 14.20 ± 2.48 (day zero) to 18.96 ± 3.26 (day three; mean ± SD). Moreover, more subjects in the control group developed clinical symptoms. Three individuals (6%) required hospitalization, compared to the ivermectin group (0%). Conclusion: Ivermectin appears to be efficacious in providing clinical benefits in a randomized treatment of asymptomatic SARS-CoV-2-positive subjects, effectively resulting in fewer symptoms, lower viral load and reduced hospital admissions. However, larger-scale trials are warranted for this conclusion to be further cemented.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/v13060989This paper is marked retracted.

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 40

  1. Lorenz, 2020, Have measures against COVID-19 helped to reduce dengue cases in Brazil?, Travel. Med. Infect. Dis., 37, 101827, 10.1016/j.tmaid.2020.101827 · doi:10.1016/j.tmaid.2020.101827
  2. Hu, 2021, Characteristics of SARS-CoV-2 and COVID-19, Nat. Rev. Microbiol., 19, 141, 10.1038/s41579-020-00459-7 · DOI · Paper page
  3. Rabi, F.A., Al Zoubi, M.S., Kasasbeh, G.A., Salameh, D.M., and Al-Nasser, A.D. (2020). SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens, 9. · DOI · Paper page
  4. Shakkour, Z., Habashy, K.J., Berro, M., Takkoush, S., Abdelhady, S., Koleilat, N., Eid, A.H., Zibara, K., Obeid, M., and Shear, D. (2020). Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury. Neuroscientist, 1073858420961078. · DOI
  5. Hammoud, 2021, Dysregulation of Angiotensin Converting Enzyme 2 Expression and Function in Comorbid Disease Conditions Possibly Contributes to Coronavirus Infectious Disease 2019 Complication Severity, Mol. Pharmacol., 99, 17, 10.1124/molpharm.120.000119 · DOI
  6. Wehbe, 2020, Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling, Front. Pharmacol., 11, 836, 10.3389/fphar.2020.00836 · DOI
  7. Zareef, 2020, COVID-19 in Pediatric Patients: A Focus on CHD Patients, Front. Cardiovasc. Med., 7, 612460, 10.3389/fcvm.2020.612460 · DOI
  8. Hall, 2020, A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease, Travel. Med. Infect. Dis., 35, 101646, 10.1016/j.tmaid.2020.101646 · DOI · Paper page
  9. Giordo, R., Zinellu, A., Eid, A.H., and Pintus, G. (2021). Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders. Molecules, 26. · DOI
  10. Younis, 2020, Hydroxychloroquine in COVID-19 Patients: Pros and Cons, Front. Pharmacol., 11, 597985, 10.3389/fphar.2020.597985 · DOI
  11. Booz, 2020, Macrophage responses associated with COVID-19: A pharmacological perspective, Eur. J. Pharmacol., 887, 173547, 10.1016/j.ejphar.2020.173547 · DOI
  12. Kinobe, R.T., and Owens, L. (2021). A systematic review of experimental evidence for antiviral effects of ivermectin and an in-silico analysis of ivermectin’s possible mode of action against SARS-CoV-2. Fundam Clin. Pharmacol. · DOI
  13. Arévalo, A., Pagotto, R., Pórfido, J., Daghero, H., Segovia, M., Yamasaki, K., Varela, B., Hill, M., Verdes, J., and Duhalde Vega, M. (2020). Ivermectin reduces coronavirus infection in vivo: A mouse experimental model. bioRxiv. · doi:10.1101/2020.11.02.363242
  14. Zhang, 2020, Ivermectin confers its cytotoxic effects by inducing AMPK/mTOR-mediated autophagy and DNA damage, Chemosphere, 259, 127448, 10.1016/j.chemosphere.2020.127448 · DOI
  15. Yang, 2020, The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer, Antivir. Res., 177, 104760, 10.1016/j.antiviral.2020.104760 · DOI · Paper page
  16. Wagstaff, 2012, Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J., 443, 851, 10.1042/BJ20120150 · DOI · Paper page
  17. Tay, 2013, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir. Res., 99, 301, 10.1016/j.antiviral.2013.06.002 · DOI · Paper page
  18. Gotz, 2016, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci. Rep., 6, 23138, 10.1038/srep23138 · DOI · Paper page
  19. Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res., 178, 104787, 10.1016/j.antiviral.2020.104787 · DOI · Paper page
  20. Jans, 2019, Inhibitors of nuclear transport, Curr. Opin. Cell Biol, 58, 50, 10.1016/j.ceb.2019.01.001 · DOI
  21. Martin, A.J., and Jans, D.A. (2021). Antivirals that target the host IMPalpha/beta1-virus interface. Biochem. Soc. Trans. · DOI
  22. Joob, 2020, COVID-19 can present with a rash and be mistaken for dengue, J. Am. Acad. Dermatol., 82, e177, 10.1016/j.jaad.2020.03.036 · DOI · Paper page
  23. Kaddoura, 2020, COVID-19 Therapeutic Options Under Investigation, Front. Pharmacol., 11, 1196, 10.3389/fphar.2020.01196 · DOI
  24. Dingens, 2020, Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak, Nat. Commun., 11, 4378, 10.1038/s41467-020-18178-1 · DOI · Paper page
  25. Kaur, H., Shekhar, N., Sharma, S., Sarma, P., Prakash, A., and Medhi, B. (2021). Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol. Rep. · DOI
  26. Thomas, 2021, Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial, JAMA Netw. Open, 4, e210369, 10.1001/jamanetworkopen.2021.0369 · DOI · Paper page
  27. Finzi, E., and Harrington, A. (2021). Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients. J. Med. Virol. · DOI
  28. DiNicolantonio, J.J., Barroso, J., and McCarty, M. (2020). Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart, 7. · DOI
  29. Ahmed, 2021, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int. J. Infect. Dis., 103, 214, 10.1016/j.ijid.2020.11.191 · DOI · Paper page
  30. Navarro, 2020, Safety of high-dose ivermectin: A systematic review and meta-analysis, J. Antimicrob. Chemother., 75, 827, 10.1093/jac/dkz524 · DOI
  31. Kampf, G., Lemmen, S., and Suchomel, M. (2020). Ct values and infectivity of SARS-CoV-2 on surfaces. Lancet Infect. Dis. · DOI
  32. Alexander, J., Tinkov, A., Strand, T.A., Alehagen, U., Skalny, A., and Aaseth, J. (2020). Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19. Nutrients, 12. · DOI · Paper page
  33. Noreen, S., Maqbool, I., and Madni, A. (2021). Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur. J. Pharmacol. · DOI · Paper page
  34. Hussein, 2021, Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19, J. Mol. Struct., 1231, 129979, 10.1016/j.molstruc.2021.129979 · DOI
  35. Westblade, 2020, SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19, Cancer Cell, 38, 661, 10.1016/j.ccell.2020.09.007 · DOI · Paper page
  36. Pujadas, 2020, SARS-CoV-2 viral load predicts COVID-19 mortality, Lancet Respir. Med., 8, e70, 10.1016/S2213-2600(20)30354-4 · DOI · Paper page
  37. Buonfrate, 2019, Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): A multicentre, open-label, phase 3, randomised controlled superiority trial, Lancet Infect. Dis., 19, 1181, 10.1016/S1473-3099(19)30289-0 · DOI · Paper page
  38. Rajter, 2021, Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study, Chest, 159, 85, 10.1016/j.chest.2020.10.009 · DOI · Paper page
  39. Gutierrez, 2008, Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats, Arzneimittelforschung, 58, 310
  40. Chaccour, C., Casellas, A., Blanco-Di Matteo, A., Pineda, I., Fernandez-Montero, A., Ruiz-Castillo, P., Richardson, M.A., Rodriguez-Mateos, M., Jordan-Iborra, C., and Brew, J. (2021). The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, 100720. · DOI · Paper page

Cited by

Metadata

Authors
Samaha, A., Mouawia, H., Fawaz, M., Hassan, H., Salami, A., Bazzal, A., Saab, H., Al-Wakeel, M., Alsaabi, A., Chouman, M., Moussawi, M., Ayoub, H., Raad, A., Hajjeh, O., Eid, A., & Raad, H.
Venue
Viruses
Publisher
MDPI AG
Published
2021-05-26
Volume
13
Issue
6
Pages
989
ISSN
1999-4915 (ISSN-L)
OpenAlex
W3164155067
Cited by
37
References
2
FWCI
2.74
Type
journal article
Language
en
Status
Retracted
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.